Mycobacterium w. Vaccine

Background: The Mycobacterium w (M.w) vaccine is a heat-killed suspension derived from a non-pathogenic mycobacterium: mycobacterium indicus pranii. As an immunotherapy, M.w is used against leprosy; the compound also shares antigens with M. tuberculosis. Its use has shown clinical improvement, rapid bacterial clearance, and enhanced immune responses to Mycobacterium leprae antigens.

M.w immunization activates macrophages and lymphocytes upon administration. It has protective efficacy against M. tuberculosis and M. leprae. As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.

Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill

Phase 3

Interventions: Drug: Suspension of heat killed (autoclaved) Mycobacterium w
Other: Placebo

Locations: 🇮🇳
All India Institute of Medical Science, Raipur, Raipur, Chhattisgarh, India
🇮🇳
All India Institute of Medical Sciences, Bhopal, Bhopal, India
🇮🇳
All India Institute of Medical Sciences, Delhi, Delhi, India

Phase 3

Interventions: Drug: Suspension of heat killed (autoclaved) Mycobacterium w
Other: Placebo

Locations: 🇮🇳
All India Institute of Medical Sciences, Bhopal, Bhopal, Madhya Pradesh, India
🇮🇳
Post Graduate Institute of Medical Education and Research, Chandigarh, India
🇮🇳
All lndia Institute of Medical Science, Delhi, Delhi, India

Not Applicable

Completed

Interventions: Drug: Suspension of heat killed (autoclaved) Mycobacterium w
Drug: Placebo

Locations: 🇮🇳
All lndia Institute of Medical Science, Delhi, Delhi, India
🇮🇳
Postgraduate Institute of Medical Education and Research, Chandigarh, India
🇮🇳
All India Institute of Medical Sciences, Bhopal, Bhopal, Madhya Pradesh, India

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.